Clinical Trials in Philadelphia

Showing 13421-13440 of 20,904 trials

Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)

NCT01676831

The objective of this study is to explore the safety and the preliminary efficacy of two concentrations (0.06% and 0.03%)gel that is applied to lesions of early stage (IA, IB,IIA) Cutaneous T Cell Lymphoma patients. This study is supported by grant 1R01FD004092-01A1 from the Office of Orphan Products Development, FDA.

Cutaneous T Cell Lymphoma

Abramson Cancer Center at Penn Medicine13 participantsStarted Feb 2012

Philadelphia, Pennsylvania, United States

TERMINATEDPhase 3< 1 mile

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

NCT00476996

This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-alpha therapy. Patients will be randomized to receive placebo, 200mg of intravenous ocrelizumab, or 500mg of i.v. ocrelizumab on days 1 and 15. A repeat course of i.v. treatment will be administered at weeks 24 and 26. All patients will receive stable doses of either concomitant methotrexate (7.5-25mg/week) or leflunomide (10-20mg po daily) and may receive additional DMARDs. The treatment period is planned for 48 weeks (until primary analysis) and then participants will enter the open label phase until the drug is commercialized. Target sample size is 1000.

Rheumatoid Arthritis

Genentech, Inc.836 participantsStarted May 2007

Anniston, Alabama, United States • Birmingham, Alabama, United States • Huntsville, Alabama, United States +263 more locations

Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

Find Trials by Condition in Philadelphia

Radiation Therapy in Treating Young Patients With Gliomas

Intraoperative Imaging of Pituitary Adenomas by OTL

Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma

Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

The Influence of Hypnotic Medications on Sleep Arousal and Its Effect on Gastroesophageal Reflux

Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

Multi-Institutional Registry for Prostate Cancer Radiosurgery

Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia

Post-Market Clinical Follow-Up to Access & Visualize the Anus, Rectum, & Distal Colon During Transanal Procedures

Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

SNORE (Smartphone Analyses of Nocturnal Obstruction by Respiratory Evaluation) SOUNDS

Parent-Adolescent Interactions and Adolescent Development

LOIS: Long-Term Follow-Up in INSITE/SIFI

A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab